Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (7): 439-442.
Previous Articles Next Articles
ZHAO Huai-quan
Received:
2016-02-03
Revised:
2016-02-03
Online:
2014-07-08
Published:
2016-03-02
CLC Number:
ZHAO Huai-quan. Patient Safety Objective and Construction of Medicine Risk Management System in Medical Institutions[J]. Chinese Journal of Pharmacovigilance, 2014, 11(7): 439-442.
[1] WHO.关于患者安全的10个事实[EB/OL].(2007-05-08)[2014-01-20].http://www.who.int/features/factfiles/patient_safety/zh/. [2] WHO.启动全球患者安全挑战[EB/OL].(2005-10-13)[2014-01-20]. http://www.who.int/mediacentre/news/releases/2005/pr50/zh/. [3] 中国医院协会.关于发布和实施《2009年度患者安全目标》的通知[EB/OL].(2009-02-13)[2014-01-20].http://www.cha.org.cn/plus/list.php?tid=223. [4] WHO.世界卫生组织及伙伴呼吁加强研究以改善患者安全[EB/OL].(2007-09-24)[2014-01-20]. http://www.who.int/mediace-ntre/news/releases/2007/pr52/zh/index.html. [5] WHO. 患者安全解决方案[EB/OL].(2007-05-01)[2014-01-20].http://www.who.int/patientsafety/solutions/patientsafety/Patient-SolutionsCHINESE.pdf. 6] 沈云玉. 门诊处方调剂内差分析及防范措施探讨[J]. 中国药物警戒,2013,10(11):693-695. [7] 卫生部.药品不良反应报告和监测管理办法[EB/OL].(2011-05-04)[2014-01-20].http://www.moh.gov.cn/mohzcfgs/pgz/201105/51770.shtml. [8] 国家食品药品监督管理总局.发布2012年药品不良反应监测年度报告[EB/OL].(2013-03-14)[2014-01-20]. http://www.sda.gov.cn/WS01/CL0051/79058.html. [9] 张晓娟,杨敏. 药物整合在防范心血管内科患者用药差错中的作用[J].中国药学杂志,2013,48(3):234-236. [10] 刘萍,张卫同,徐子玲,等.门诊药房常见的发药差错原因与防范措施分析[J].中国药房,2013, 24(37):3547-3550. [11] 田旭,孙丽蕊,张红梅,等.品管圈活动在提高我院门诊处方合格率中的应用[J].中国药房,2013,24(25):2344-2346. [12] 中国药学会医院药学专业委员会.高危药品分级管理策略及推荐目录[EB/OL].(2012-03-31)[2014-01-20].http://www.cpahp.org.cn/ccyyf/news/201203/1435.htm. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||